Half Title Page.
List of Contributors.
About the Editor.
Epidemiology, Etiology, and Pathophysiology.
2: Etiology (Risk Factors for Bladder Cancer).
3: Pathophysiology of Bladder Cancer.
5: Physical Examination.
6: Urine Cytology and Urinary Biomarkers.
8: Bladder Cancer: Imaging.
9: Transurethral Resection of Bladder Tumors.
10: Recent Technological Advances in Cystoscopy for the Detection of Bladder Cancer.
Pathology and Staging.
11: Histological Classification of Bladder Tumors.
12: Tumor, Nodes, Metastases (TNM) Classification System for Bladder Cancer.
Treatment for Nonmuscle Invasive Bladder Cancer (NMIBC).
13: Risk Factors for Recurrence and Progression of Nonmuscle Invasive Bladder Cancer.
14: Treatment for TaT1 Tumors.
15: Treatment for Carcinoma In Situ.
16: Treatment for T1G3 Tumor.
17: Single, Immediate, Postoperative Intravesical Chemotherapy.
18: Second Transurethral Resection of Bladder Cancer.
19: Intravesical Chemotherapy.
20: Immunotherapy: Bacille Calmette–Guérin.
21: Treatment of Failure of Intravesical Therapy.
Treatment for Muscle-Invasive Bladder Cancer (MIBC).
22: Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
23: Radical Cystectomy (RC) with Urinary Diversion.
24: Open Techniques and Extent (Including Pelvic Lymphadenectomy).
25: Morbidity, Mortality, and Survival for Radical Cystectomy.
26: Adjuvant Chemotherapy.
27: Bladder-Sparing Treatments.
28: Quality of Life in Bladder Cancer Patients.
Chemotherapy for Metastatic Bladder Cancer.
29: Surveillance for Non-Muscle-Invasive Bladder Cancer.
30: The Surveillance for Muscle-Invasive Bladder Cancer (MIBC).
31: Novel and Emerging Surveillance Markers for Bladder Cancer.
Future Perspective in Bladder Cancer.
33: Genetic Testing, Genetic Variation, and Genetic Susceptibility.
34: CRISPR-Genome Editing.
35: Personalized Medicine.